Spanish journal wins lawsuit over COX-2 drug editorial

COX-2 inhibitors--lessons in drug safety.

Approximately six years after the cyclooxygenase-2 (COX-2) inhibitors were approved for use in the United States, the results of three randomized, placebo-controlled trials provide new evidence about the cardiovascular risks of rofecoxib, celecoxib, and valdecoxib. 1-3 The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial, a study of patients with a history of colorectal adenomas, was stopp...

Editorial Letter into Spanish

Es un placer para mí presentar este número monográfico cuyo objetivo es dar a conocer el trabajo de algunos de los principales equipos de investigación españoles en cognición y esquizofrenia. Se trata en todos los casos de equipos con amplia experiencia internacional y con líneas de trabajo punteras en cada especialidad. Aunque todos los trabajos cuentan con la calidad suficiente para optar a s...

Editorial from Journal Editors

Patient care is the primary focus of the orthopaedic profession. The enhancement of patient care has required and will continue to require orthopaedic surgeons to collaborate productively with industry to develop new medical technology and techniques that improve patient care. The relationship between orthopaedic surgeons and industry is of critical importance to the shared ultimate goal of imp...

Coors Wins Battle Over Beer Labels

Slow but steady wins the drug race

Without the SNF-6 acetylcholine transporter (bottom) mutant muscles fall apart. K im /M ac m ill an they are mutant for various members of the dystrophinglycoprotein complex (DGC), which links intracellular actin to extracellular laminin. But now, Hongkyun Kim, Steven McIntire (University of California, San Francisco, CA), and colleagues suggest that loss of the DGC results in loss of an associ...